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Abstract
Background: Benign infantile convulsions and paroxysmal dyskinesia are episodic cerebral disorders that can share
common genetic bases. They can be co-inherited as one single autosomal dominant trait (ICCA syndrome); the disease ICCA
gene maps at chromosome 16p12-q12. Despite intensive and conventional mutation screening, the ICCA gene remains
unknown to date. The critical area displays highly complicated genomic architecture and is the site of deletions and
duplications associated with various diseases. The possibility that the ICCA syndrome is related to the existence of large-
scale genomic alterations was addressed in the present study.
Methodology/Principal Findings: A combination of whole genome and dedicated oligonucleotide array comparative
genomic hybridization coupled with quantitative polymerase chain reaction was used. Low copy number of a region
corresponding to a genomic variant (Variation_7105) located at 16p11 nearby the centromere was detected with statistical
significance at much higher frequency in patients from ICCA families than in ethnically matched controls. The genomic
variant showed no apparent difference in size and copy number between patients and controls, making it very unlikely that
the genomic alteration detected here is ICCA-specific. Furthermore, no other genomic alteration that would directly cause
the ICCA syndrome in those nine families was detected in the ICCA critical area.
Conclusions/Significance: Our data excluded that inherited genomic deletion or duplication events directly cause the ICCA
syndrome; rather, they help narrowing down the critical ICCA region dramatically and indicate that the disease ICCA genetic
defect lies very close to or within Variation_7105 and hence should now be searched in the corresponding genomic area
and its surrounding regions.
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Introduction
Benign familial infantile seizures (BFIS) (MIM 601764, 605751,
607745, 612627) correspond to non-febrile and focal convulsions
with onset at age 3–12 months and a favorable outcome.
Although their relative prevalence is not known with precision,
they may be one of the most common epilepsy in the two first
years of life[1]. BFIS is an autosomal dominant disorder with
incomplete penetrance. Benign infantile seizures (BIS) may also
be associated with paroxysmal dyskinesia (PD) in the context of
the autosomal dominant ICCA (Infantile Convulsions with
paroxysmal ChoreoAthetosis) syndrome (MIM 602066)[2–5].
PD represent a rare group of neurological movement disorders
characterized by episodes of involuntary abnormal movements
(dyskinesia) that correspond to attacks of choreoathetosis or
dystonia. PD are heterogeneous at both the clinical and genetic
levels, with several genes mapped and a subset identified at
chromosomes 1p34 (SLC2A1 gene) and 2q35 (MR-1 gene)[6–8].
The epileptic origin of PD has long been a matter of debate[4,5]
and PD have even been classified as reflex epilepsies. Indeed,
attacks of PD and epileptic seizures have several characteristics in
common: both are paroxysmal in nature with a tendency to
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13750spontaneous remission, and a subset of PD responds well to
anticonvulsants.
In 1997, description of the familial ICCA syndrome in four
families from Northern of France and linkage to chromosome
16p12-q12 provided the first genetic evidence for common
mechanisms shared by BFIS and by PD[2]. Since then, numerous
studies have confirmed linkage of ICCA pedigrees[3,9–11] to the
same ICCA genomic area, strongly suggesting genetic homoge-
neity of the ICCA syndrome. Indeed, no ICCA family has ever
been excluded for linkage to the ICCA genomic area amongst the
27 families that have been genotyped so far[2,3,9–14]. Noteworth-
ingly, a majority of pure BFIS families[14–17] also showed linkage
to the same ICCA genomic area. This suggested that the BFIS and
ICCA syndromes that are linked to 16p12-q12 may be allelic.
However, there may be several homologous disease genes in the
ICCA region, where nearly identical copies of genes have been
described[5]. If there were more than one disease gene in the
ICCA region, determining a single and consensus critical region
could lead to dramatic errors – notwithstanding artifacts of wrong
genome assembly. To date, no such disease gene has been
identified yet despite quite intensive conventional mutation
screening (Roll, Massacrier, De ´lepine, Lathrop & Szepetowski,
our unpublished data). The pericentromeric ICCA area displays
highly duplicated large DNA sequences[18,19] and this may
present an enormous challenge for mutation search. Furthermore,
the occurrence of large-scale genomic rearrangements such as
deletions and duplications would be favored in the context of such
a complicated genomic architecture and hence should be
considered in physiological as well as in pathological conditions.
Indeed, copy number variations of various sizes and locations have
been reported in the recent years at human chromosome 16p12-
q12 in normal individuals[19–23] (database of genomic variants at
http://projects.tcag.ca/variation/?source=hg18), and deletion/
duplications at 16p11.2 have been associated with higher risk for
developmental disabilities[24], for autism spectrum disor-
ders[25,26], for severe obesity[27,28], for schizophrenia[29] and
for various other phenotypes such as speech, language and
cognitive impairments, behavior problems or epileptic sei-
zures[30]. Generally, an increasing number of human pathologies
including nervous system diseases, have proved to be genomic
disorders arising either de novo or as inherited traits[31,32]. In the
present study and using a combination of whole genome and
dedicated oligonucleotide array comparative genomic hybridiza-
tion (CGH) coupled with quantitative polymerase chain reaction
(qPCR), we have explored the possibility that the ICCA syndrome
is associated with genomic alterations in the pericentromeric
region of human chromosome 16.
Materials and Methods
Ethics Statement
All experiments were conducted in accordance with the
Declaration of Helsinki and all procedures were carried out with
the adequate understanding and written consent of the subjects,
and after approval from the appropriate ethical committees
(‘Comite ´ Consultatif de Protection des Personnes dans la
Recherche Biome ´dicale de Marseille II’, St Paul Centre Hospital,
Marseille; ‘Comite ´ Consultatif de Protection des Personnes dans la
Recherche Biome ´dicale d’Alsace nu19 and ‘Comite ´ de Protection
des Personnes ‘‘EST IV’’’, Strasbourg University Hospital).
Patients and controls
All ICCA patients and families studied here have already been
reported[2,3,13,33]. The terms ‘ICCA patient’ and ‘ICCA
family’refer to the ICCA syndrome, which is characterized by a
variable presentation of BIS and PD in the same patient, or in
different patients in one given family. Hence all individuals in a
given ICCA family do have the ICCA syndrome inherited as one
single autosomal dominant trait (and hence one single genetic
defect is inherited), whether they present with BIS, with PD, or
with both associated. DNAs from patients and from heatlhy
controls were extracted, purified and validated (NanoDrop
TM
1000, Thermo Fisher Scientific) from fresh blood samples
according to standard procedures.
CGH-array (aCGH) analyzes
A first set of experiments was performed using a 244 K Human
CGH (G4411B) microarray (Agilent Technologies, Santa Clara,
CA, USA). In all experiments, opposite sex-matched DNA from a
pooled human female or male individual (Promega, Madison, WI)
was used as the reference. Oligonucleotide aCGH processing was
performed as detailed in the manufacturer’s protocol (CGH-
v4_91; http://www.agilent.com). Data were extracted from
scanned images using an Agilent Scanner G2505B and feature
extraction software (version A. 9.1.1.1, Agilent). Raw data text
Files from the latter were then imported for analysis into CGH
Analytics 3.4.40. Aberrations were detected with the ADM2
algorithm and filtering options of a minimum of five probes and
abs(log2Ratio) 0.3. Aberration segments were individually re-
viewed using build 35, hg17 of UCSC.
A second series of experiments was performed using a 44,000
oligonucleotides Agilent TechnologiesH custom microarray, en-
riched in the region 16p12.1q12.1 between nucleotide (nt)
positions 27,596,583 and 45,502,600. Design of the custom
microarray was done at Imaxio (http://www.avidis.fr/index.php)
and 12,305 oligonucleotides were added in this specific region,
allowing an average resolution of 642 bp between two consecutive
oligonucleotides (centromeric region was excluded). Eight hundred
nanograms of patient’s DNA or of reference DNA (Human
Genomic DNA, PromegaH, Madison) were digested respectively
with AluI and RsaI (PromegaH, Madison). Each digestion product
was labeled by random priming with Cyanine 5 for patients or
Cyanine 3 for the reference according to the Genomic DNA
Labeling Kit protocol (AgilentH, Santa Clara). After columns-
purification with Microcon (MilliporeH, Bedford), each probe was
denatured and pre-annealed with 50 mg of human Cot-1 DNA
(InvitrogenH, California). Hybridization was performed at 65uC
for 24 hours. After washing, array was analyzed by Feature
ExtractionH 9.5 software. Interpretation of the results was carried
out with the CGH AnalyticsH 3.5.14 software, set with the
following parameters: ADM-2, threshold: 6.0, window: 0.5 Mb,
cut-off: 0.25.
Quantitative PCR (qPCR) experiments
PCR primers were designed for two specific subregions
(ICCA.SRa and ICCA.SRb, respectively) situated within Varia-
tion_7105, as well as for the 10p14 GATA3 (GATA binding
protein 3) control gene, using the Universal Probe Library Assay
Design Center at https://www.roche-applied-science.com/. No
copy-number change has been described in the human genome
(Database of Genomic variants at http://projects.tcag.ca/varia-
tion/) for control GATA3 amplicon and no genomic rearrange-
ment was detected in the GATA3 genomic area in the first series of
whole genome CGH experiments. Primers were: for ICCA.SRa,
forward 59-caagtgagttcttgaaacatcca, and reverse 59-tgaaatc-
catccctgctgat; for ICCA.SRb, forward 59-ggttatctagagacaaagtg-
cattga, and reverse 59-tgggaaccccaaacttaaca; for GATA3, forward
59-tgcctttggtttttagacagg, and reverse 59-tcagcatcagaattccattcc.
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SYBR Green I Master (Roche) in the LightCyclerH 480 system
(Roche). All primer pairs were optimized to ensure specific
amplification of the PCR product and the absence of any primer
dimer. qPCR standard curves were set up for all. Quantification
was calculated using the comparative Ct method. Relative
quantification (DCt) was performed using GATA3 as reference
gene. Each qPCR experiment contained triplicates of control or
patient samples for all primer pairs.
Statistical analyzes
Statistical significance was assessed using Mann-Whitney test
and Student t-test for the comparison of DCt mean values between
patients and controls or between carrier and non-carrier of the
disease haplotype in pedigree A. For the analysis of DCt values, all
possible combinations of nine affected individuals taken from their
corresponding nine families were compared to controls, as a
method of resampling. A hierarchical cluster analysis was used to
identify clusters of individuals taking into consideration the two
DCt values corresponding to the ICCA.SRa and ICCA.SRb
subregions. Fisher’s exact test was used to compare the frequencies
between patients and controls in Cluster1.
Results and Discussion
Whole genome CGH analysis suggests higher frequency
of low copy number of Variation_7105 in ICCA families
As a first attempt to test for the possible relationship of the
ICCA syndrome with genomic events, one patient was randomly
taken from each of five ICCA families from Northern France
previously reported, i.e. pedigrees A to D[2] plus one additional
pedigree thereafter designated as ICCA-2002[13] (Figure 1).
Whole genome CGH analysis using Agilent 244K high density
microarray revealed the existence of low copy number of a 1.7
megabases (Mb) genomic area at chromosome 16p11.2 (Figure 2)
in four out of the five ICCA patients (Figure S1). In those four
patients, the genomic region extended from 31,862,577 nucleotide
(nt) position on its telomeric side, to 33,539,082 nt on its
centromeric side (positions according to the hg18 human reference
sequence NCBI Build 36.1 at UCSC website: http://genome.ucsc.
edu/). This corresponded roughly to a copy number variation
(CNV) known as Variation_7105 (from 31,974,497 nt to
33,760,388 nt, NCBI Build 36.1, according to the database of
genomic variants at http://projects.tcag.ca/variation/). Varia-
tion_7105 has been identified previously in eight out of 50 control
individuals who also originated from Northern France and using
Agilent 185K and custom microarrays[23]. In the five patients
studied here, no other genomic alteration was consistently detected
in the ICCA area. In particular, the more telomeric deletion/
duplication events reported at 16p11.2 in other patients with
various phenotypes such as autism, schizophrenia, speech/
language delay, obesity, or epileptic seizures[24–29] were not
found. Particularly, the de novo 544-kb deletion at 16p11.2 (nt
29,560,500 to 30,104,842) that was recently reported in one
atypical patient with kinesigenic PD (PKD) and with other clinical
features including verbal learning disability and DOPA-responsive
parkinsonism, and with possible infantile-onset convulsions[34],
was not detected in any of the five and unrelated ICCA patients
studied here. The tendency (4/5 patients here, as compared with
8/50 controls in previous study) towards a possible increase in the
frequency of low copy number of Variation_7105 located right
within the critical ICCA area, that in turn had previously and
independently shown linkage with the ICCA syndrome, led us to
further investigate in the patients the ICCA region at the genomic
level.
Quantitative PCR confirms a shift towards low copy
number of Variation_7105 in the ICCA families
In order to confirm the data obtained by whole genome CGH
arrays and to extend the analysis to more ICCA patients and to
control individuals, quantitative polymerase chain reaction
(qPCR) experiments were performed. Primers for qPCR were
selected in two specific subregions (thereafter named ICCA.SRa
and ICCA.SRb, respectively) of Variation_7105 that appeared
unique as determined by in silico analysis based on the UCSC
human genome assembly (NCBI Build 36.1). qPCR was
performed on the five ICCA patients previously used for whole
genome CGH array analyzes as well as on four patients from
additional ICCA families (pedigrees P1, P2, P3 and P7 in Figure 1)
also of European descent [33]. In each of the nine ICCA families,
one patient was randomly chosen for the analysis (Figure 1). In
parallel, 50 unrelated and healthy individuals (25 males and 25
females) of European origin were also analyzed (control individ-
uals). The qPCR data clearly showed a shift towards low copy
number in each of the ICCA.SRa and ICCA.SRb subregions in
the nine ICCA patients (thereafter designated as series S1) as
compared with the 50 control individuals (Figure 3A). The
difference between ICCA patients and control individuals was
statistically highly significant (p=0.0036 for ICCA.SRa and
p=0.0001 for ICCA.SRb, Mann-Whitney test; p=0.0049 for
ICCA.SRa and p=0.0001 for ICCA.SRb, unpaired t-test with
Welch’s correction). One additional patient was randomly taken
from a family of Chinese origin (patient II.4 in pedigree E)[3]
(Figure 1) that had shown significant linkage to the ICCA region.
Although not taken into account for the statistics because of
different ethnic origin of pedigree E, this patient yielded amongst
the lowest DCt values (Figure 3). When the qPCR data were
analyzed in the control individuals, no significant difference was
found between males and females (p=0.6671, Mann Whitney test,
and p=0.9757, unpaired t-test, for marker ICCA.SRa;
p=0.4879, Mann Whitney test, and p=0.4389, unpaired t-test,
for marker ICCA.SRb); hence the significant data depicted above
were not due to any kind of gender bias. Importantly, the DNA
pool (Cont Pool 1) that had been used as control DNA in the
previous whole genome CGH array experiments showed DCt
values in the same range as those obtained when considering the
mean of the 50 control individuals DNAs mentioned above and as
the mean DCt value obtained in another independent DNA pool
(Cont Pool 2) of 50 novel healthy individuals (Figure 3A); this
confirmed that the low copy numbers as detected by the CGH
array analyses, had not been found because of a relative high copy
number in the control DNA pool (Cont Pool 1) used for CGH.
Figure 1. Pedigrees of the ten ICCA families. All pedigrees have already been reported: A to D[2], E[3], ICCA-2002[13], P1 to P3 and P7[33].
Pedigree A is also depicted in Figure S2. Black squares/circles: patients with ICCA syndrome (benign infantile seizures and/or paroxysmal dyskinesia).
Empty squares/circles: unaffected individuals. Dotted square: phenotype unknown. Asterisks indicate the patients with DNAs available. Patients with
underlined IDs correspond to those that were randomly selected for the first series (series S1) of qPCR experiments and that were used for
hierarchical cluster analysis of qPCR data (Figure 3, Figure S2). wg: corresponds to the patients used for whole genome CGH (comparative genome
hybridization) array studies. cu: corresponds to the patients and to the non-affected individuals used for custom CGH array studies.
doi:10.1371/journal.pone.0013750.g001
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S1) and in the statistical analyses depicted just above were taken
from nine corresponding ICCA families by random selection prior
to the analysis; however, biased intrafamilial selection towards
patients with low copy numbers could have occurred by chance.
To address this issue and as the data were highly significant and
comparable for both qPCR markers, all available DNAs from the
other affected patients in each ICCA family were analyzed by
qPCR for one of the two markers (marker ICCA.SRb) and the
statistical analyses were redone for all possible combinations
(30,240 in total) of nine patients (one per family). All resamplings
of patients differed significantly from controls (p=0.005 with a
95% confidence interval of 0.0049 to 0.0051).
Clustering and intrafamilial qPCR analyzes
While genetic variation is inherently discrete at the nucleotide
level, qPCR measurements are less discretely distributed because
of measurement noise[35]. This indeed was oberved here when
Figure 2. Schematic map of the pericentromeric region of human chromosome 16. (A) ICCA consensus region[5]. cen: centromere. nt: nucleotides.
(B) Location of the copy number variation (CNV) in the ICCA patients (‘Identified variation’) and of the previously reported CNV (Variation_7105)[23]. Physical
locations are indicated according to the NCBI Build 36.1 version (hg18) of the human genome sequence assembly at University of California Santa Cruz
website (http:genome.ucsc.edu/). The most updated version (hg19) of the human genome sequence assembly has different nt positions with respect to
hg18: for instance, hg18 position 31,862,577 corresponds to 31,955,076 in hg19, and hg18 position 33,539,082 to position 33,631,581 in hg19.
doi:10.1371/journal.pone.0013750.g002
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and ICCA.SRb, respectively) independendtly (Figure 3A). In
contrast, a subset of the DCt values obtained in the nine ICCA
patients of series S1 clustered into discrete groups when the two
markers were considered together (Figure 3B; Figure S2). This was
done by using a hierarchical cluster analysis in order to identify
clusters of individuals, and by taking into consideration the two
DCt values corresponding to the ICCA.SRa and ICCA.SRb
subregions, respectively. Two clusters corresponding to individuals
with low DCt values, and hence to individuals with low copy
number of Variation_7105 (Clusters 1 & 2 in Figure 3B), could
indeed be statistically isolated from all other values. In particular,
Cluster 1 corresponded to the lowest combined DCt values: it
comprised six out of the nine ICCA patients, but only four out of
50 control individuals (p=0.0003, Fisher’s exact test).
Overall, the qPCR data confirmed that ICCA patients have low
copy number of the genomic area corresponding to Varia-
tion_7105 with higher frequency than control individuals. This
was further confirmed by intrafamilial analysis. As pedigree A[2]
was by far the largest ICCA pedigree ever described, we also
performed the statistical analysis for DCt values of subregion
ICCA.SRb within this family, by comparing all individuals of
pedigree A who carried the disease haplotype with those who did
not carry the disease haplotype. DCt values in haplotype carriers
were lower than the DCt values of non carrier individuals and this
difference was statistically significant (Mann-Whitney test,
p=0.0307; unpaired t-test, p=0.0337) (Figure S3).
Dedicated CGH array excludes a direct causal role for low
copy number of Variation_7105
As mentioned above, the genomic area of low copy number in
the ICCA families corresponded to the previously described
Variation_7105 (http://projects.tcag.ca/variation/)[23]. How-
ever, the possibility remained, that slight differences in the
genomic variant existed between ICCA patients and control
individuals and hence that the genomic alteration in the patients
was directly causing the phenotype. To address this issue, a more
precise CGH analysis was performed by designing a chromosome
16p12.1-q12.1 dedicated 4644 custom Agilent microarray
enriched with 12,305 oligonucleotides between 27.5 Mb and
45.5 Mb. The novel microarray data confirmed and extended the
whole genome CGH array data and the qPCR experiments
depicted above in all nine ICCA patients of series S1 that were re-
analyzed (Figure S4); moreover and as already indicated by our
whole genome CGH array analysis, no copy number variation of
the more telomeric region deleted in one peculiar patient with
PKD and possibly infantile seizures[34], was found in any of the
ICCA patients analyzed here with the chromosome 16p12.1-
q12.1 enriched microarray. Genomic variant corresponding to
Variation_7105 looked identical in size and overall copy number
(Figure S4, panel A) between the six ICCA patients and the
unaffected control individual (nu11) who all corresponded to
Cluster 1-DNAs according to the qPCR experiments depicted
above (Figure 3B, Figure S2). Similar results (Figure S4, panel B)
were obtained when comparing DNAs of Cluster 2 corresponding
to patient II.1 in pedigree C with DNAs from control individuals
nu17 and 18. To further confirm the absence of any difference in
the genomic region corresponding to Variation_7105 between
patients and control individuals, direct competitive hybridization
of patient II.5 in pedigree D versus control nu11, both belonging
to Cluster 1 (Figure 3B, Figure S2), was performed (Figure S4,
panel C); as expected, this experiment did not reveal any
significant difference. Intrafamilial comparison between affected
individual III.4 in pedigree A (haplotype carrier) and his
unaffected and non-haplotype carrier mother (II.2) (Figure 1,
Figure S3), and who displayed similar DCt values (Figure S3), was
also done by direct competitive hybridization: again, there was no
difference in the size and the copy number of Variation_7105
(Figure S4, panel D).
The disease ICCA genetic defect lies close to or within
Variation_7105
Altogether, these results confirmed that the genomic variant
(Variation_7105) detected in the ICCA patients, although much
more frequent than in control individuals, was very unlikely to
directly cause the phenotype as it was also detected with no
apparent difference in control individuals. Rather, the higher
frequency of low copy number of Variation_7105 in the ICCA
patients likely corresponded to linkage disequilibrium (LD)
between Variation_7105 and the as yet unknown ICCA mutant
allele. In the present case, the genetic defect causing ICCA could
then be situated in the vicinity of Variation_7105 boundaries.
Generally, the existence and complexity of LD between a given
CNV and its neighboring single nucleotide variations (SNPs) has
already been discussed[36]. Moreover, physiological inversions
that would make it the picture more complicated have already
been described in control individuals at chromosome 16p11[37].
The disease gene could also map right within Variation_7105.
The corresponding genomic area is very gene-poor (http://
genome.ucsc.edu/). Itc o n t a i n sa tl e a s tf o ur nearly-identical
copies of the TP53TG3 gene encoding a tumor suppressor p53-
inducible protein[38]. TP53TG3 h a db e e ne x c l u d e db ym u t a t i o n
screening in a previous study[39] but the detection of one mutant
allele amongst several copies of the wild type allele could have
been problematic. Interestingly, Variation_7105 also contains
several highly homologous copies of the SLC6A10P pseudogene
(Genbank NR_003083) corresponding to the family of creatine
transporters; SLC6A10P sequences are indeed paralogous to the
X-linked SLC6A8 gene (also known as the CT1 creatine
transporter)[40] that is involved in various brain disorders
including mental retardation and epileptic seizures[41]. Al-
though SLC6A10P does not contain any open reading frame
corresponding to a full-length creatine transporter[41,42], the
relationship with SLC6A8 may not be coincidental by chance and
warrants further investigations. As a matter of fact, SLC6A10P
transcripts have been detected in the human fetal and adult
brain[43]. In addition to TP53TG3 and SLC6A10P, the existence
of other genes or of sequences for small non-coding RNAs not yet
detected in this complicated and pericentromeric area, cannot be
excluded.
Figure 3. Quantitative PCR studies. Two specific subregions (ICCA.SRa and ICCA.SRb) of Variation_7105 were analyzed in nine unrelated ICCA
patients (series S1) and in unrelated control individuals. (A) Comparisons of DCt values for ICCA.SRa (left) and ICCA.SRb (right) between ICCA patients
and controls. (**) indicates P,0.01. (***) indicates P,0.001. DCt values of the control DNA pool (Promega) used for whole genome CGH array
experiments (Cont Pool 1), of the pool of 50 DNAs of control individuals (Cont Pool 2), and of patient II.4 from pedigree E of Chinese origin[3], are also
indicated. (B) Clustering analysis of DCt values for ICCA.SRa and ICCA.Srb in ICCA patients (red triangles) and controls (blue dots). Patient II.4 of
pedigree E[3] is also indicated (purple square). The two clusters (Cluster 1, pink circle; Cluster 2, brown circle) that could be statistically isolated from
all other values are indicated (see also Figure S2).
doi:10.1371/journal.pone.0013750.g003
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We have shown here that low copy number of a 16p11 genomic
variation (Variation_7105) situated in the critical region where the
ICCA gene maps, is significantly much more frequent in ICCA
patients than in control individuals. The other 16p11.2 disease-
associated variations that had been detected in autism, in
shizophrenia, in speech/language delay, in obesity, in epileptic
seizures[24–30] or even in paroxysmal dyskinesia[34], were not
detected in any of the patients tested here. Altogether, these data
should now be taken into account in future studies that aim at
identifying the genetic defect underlying the ICCA syndrome, by
focusing on the 16p11 genomic area corresponding to Varia-
tion_7105 and to its surrounding regions. As compared with
previously published data that led to define a critical ICCA region
more than 20 Megabases large [5], narrowing down the critical
region to Variation_7105 and to its immediate vicinity, clearly
represents a significant progress.
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Figure S1 Data of the whole genome CGH (comparative
genome hybridization) array analysis (244K array from AgilentH).
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